• +1-646-491-9876
    • +91-20-67278686

    Search

    Anal Cancer-Pipeline Review H2 2017

    Anal Cancer-Pipeline Review H2 2017

    • Report Code ID: RW00011022661
    • Category Life Sciences
    • No. of Pages 198
    • Publication Month Aug-17
    • Publisher Name Global Markets Direct
    Anal Cancer-Pipeline Review, H2 2017

    Summary

    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer-Pipeline Review, H2 2017, provides an overview of the Anal Cancer (Oncology) pipeline landscape.

    Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area. Predisposing factors include HPV infections, smoking and lowered immunity.

    Report Highlights

    Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anal Cancer-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 10, 3 and 4 respectively.

    Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The pipeline guide provides a snapshot of the global therapeutic landscape of Anal Cancer (Oncology).
    -The pipeline guide reviews pipeline therapeutics for Anal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Anal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Anal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Anal Cancer (Oncology)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Anal Cancer (Oncology).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Anal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Global Markets Direct Report Coverage 5
    Anal Cancer-Overview 6
    Anal Cancer-Therapeutics Development 7
    Pipeline Overview 7
    Pipeline by Companies 8
    Products under Development by Companies 10
    Anal Cancer-Therapeutics Assessment 11
    Assessment by Target 11
    Assessment by Mechanism of Action 13
    Assessment by Route of Administration 15
    Assessment by Molecule Type 17
    Anal Cancer-Companies Involved in Therapeutics Development 19
    Advaxis Inc 19
    Amgen Inc 19
    Atara Biotherapeutics Inc 20
    Bayer AG 20
    BeiGene Ltd 21
    Eli Lilly and Company 21
    Immunovaccine Inc 22
    ISA Pharmaceuticals BV 22
    Merck & Co Inc 23
    Ono Pharmaceutical Co Ltd 23
    Oryx GmbH & Co KG 24
    PDS Biotechnology Corp 24
    Sun Pharma Advanced Research Company Ltd 25
    Taiwan Liposome Company Ltd 25
    Anal Cancer-Drug Profiles 26
    ATA-368-Drug Profile 26
    axalimogene filolisbac-Drug Profile 27
    axalimogene filolisbac second generation-Drug Profile 46
    BAY-1125976-Drug Profile 47
    BGBA-317-Drug Profile 48
    cisplatin-Drug Profile 51
    CUE-101-Drug Profile 52
    DPXE-7-Drug Profile 53
    ISA-101-Drug Profile 55
    nivolumab-Drug Profile 59
    paclitaxel albumin free-Drug Profile 108
    panitumumab-Drug Profile 109
    PDS-0101-Drug Profile 115
    pembrolizumab-Drug Profile 117
    prexasertib-Drug Profile 178
    TLC-388-Drug Profile 180
    Vicoryx-Drug Profile 182
    Anal Cancer-Dormant Projects 183
    Anal Cancer-Discontinued Products 184
    Anal Cancer-Product Development Milestones 185
    Featured News & Press Releases 185
    Appendix 196
    Methodology 196
    Coverage 196
    Secondary Research 196
    Primary Research 196
    Expert Panel Validation 196
    Contact Us 196
    Disclaimer 197

    List of Tables
    Number of Products under Development for Anal Cancer, H2 2017
    Number of Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Anal Cancer-Pipeline by Advaxis Inc, H2 2017
    Anal Cancer-Pipeline by Amgen Inc, H2 2017
    Anal Cancer-Pipeline by Atara Biotherapeutics Inc, H2 2017
    Anal Cancer-Pipeline by Bayer AG, H2 2017
    Anal Cancer-Pipeline by BeiGene Ltd, H2 2017
    Anal Cancer-Pipeline by Eli Lilly and Company, H2 2017
    Anal Cancer-Pipeline by Immunovaccine Inc, H2 2017
    Anal Cancer-Pipeline by ISA Pharmaceuticals BV, H2 2017
    Anal Cancer-Pipeline by Merck & Co Inc, H2 2017
    Anal Cancer-Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
    Anal Cancer-Pipeline by Oryx GmbH & Co KG, H2 2017
    Anal Cancer-Pipeline by PDS Biotechnology Corp, H2 2017
    Anal Cancer-Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
    Anal Cancer-Pipeline by Taiwan Liposome Company Ltd, H2 2017
    Anal Cancer-Dormant Projects, H2 2017
    Anal Cancer-Discontinued Products, H2 2017

    List of Figures
    Number of Products under Development for Anal Cancer, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    Advaxis Inc
    Amgen Inc
    Atara Biotherapeutics Inc
    Bayer AG
    BeiGene Ltd
    Eli Lilly and Company
    Immunovaccine Inc
    ISA Pharmaceuticals BV
    Merck & Co Inc
    Ono Pharmaceutical Co Ltd
    Oryx GmbH & Co KG
    PDS Biotechnology Corp
    Sun Pharma Advanced Research Company Ltd
    Taiwan Liposome Company Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//anal-cancer-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//anal-cancer-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//anal-cancer-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments